Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed. This open-label, phase 3 trial evalua...

Full description

Bibliographic Details

Published in:	Clinical infectious diseases
Main Authors:	Goswami, Jaya, Cardona, Jose F, Caso, Jorge, Hsu, Denise C, Simorellis, Alana K, Wilson, Lauren, Dhar, Rakesh, Wang, Xiaowei, Kapoor, Archana, Collins, Avi, Righi, Vinicius, Lan, Lan, Du, Jiejun, Zhou, Honghong, Stoszek, Sonia K, Shaw, Christine A, Reuter, Caroline, Wilson, Eleanor, Das, Rituparna
Format:	Journal Article
Language:	English
Published:	United States 23.09.2025
Subjects:	mRNA RSV vaccine revaccination respiratory syncytial virus safety immunogenicity
ISSN:	1537-6591, 1537-6591
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!